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Available online 6 July 2011Objective: To explore the utility of applying growth mixture models (GMMs) in secondary
analyses of clinical trials to identify sources of variability in data reported by patients with
COPD.
Methods: Analyses were performed on data from two 6-month clinical trials comparing
indacaterol and open-label tiotropium or blinded salmeterol and the first six months of a 12-
month trial comparing indacaterol and blinded formoterol. Latent growth model (LGM)
analyses were conducted to explore the response of the SGRQ Symptoms score from baseline to
six months and GMM analyses were evaluated as a method to identify latent classes of
differential responders.
Results: Variability in SGRQ Symptom scores was found suggesting subsets of patients with
differential response to treatment. GMM analyses found subsets of non-responders in all trials.
When the responders were analyzed separately from non-responders, there were increased
treatment effects (e.g., symptoms score improvement over six months for whole groups:
indacaterol=8–12 units, tiotropium=7 units, salmeterol=9 units, formoterol=11 units.
Responder subgroup improvement: indacaterol=9–21 units, tiotropium=7 units, salme-
terol=10 units, formoterol=20 units). Responders had signiﬁcantly different baseline SGRQ
Symptom scores, smoking history, age, and mMRC dyspnea scores than non-responders.
Conclusions: Patients with COPD represent a heterogeneous population in terms of their
reporting of symptoms and response to treatment. GMM analyses are able to identify sub-
groups of responders and non-responders. Application of this methodology could be of value
on other endpoints in COPD and in other disease areas.
© 2011 Elsevier Inc. Open access under CC BY-NC-ND license. Keywords:
COPD
Longitudinal analysis
Growth mixture model
Latent growth model
Clinical trials1. Introduction
It is very common to observe heterogeneity in treatment
response in clinical trials and interest in identifying andx: +44 161 434 8232
ggli@novartis.com
, pjones@sgul.ac.uk
Y-NC-ND license. .categorizing this has grown in recent years [1–4]. A challenge
facing researchers is how best to examine whether there are
patterns to this variability and the sources of the variability.
For example, subpopulations may exist within a larger
heterogeneous population that show a differential growth
trajectory which is masked when groupmeans as a whole are
considered. In terms of treatment, identifying and categoriz-
ing differential responders have implications for trial devel-
opment and clinical management, with the potential for the
information to facilitate the targeting of patients most likely
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modeling (LGM) and growth mixture modeling (GMM) may
yield more precise parameter estimates than traditional
analysis methods and explain more of the variance in an
outcome [5,6]. These methods have been implemented using
clinical trial results in the treatment of Alzheimer's disease [2]
and depression [3,4], with GMMs successfully identifying
subgroups of responders with differential growth trajectories.
Therefore, analyzing group means as a whole may mask
important differences in treatment response between unob-
served subgroups. Although studies have established that
there is variability in treatment response for chronic
obstructive pulmonary disease (COPD) patients [7,8], very
little is known about such differential response and which
patients are most likely to beneﬁt most/least [9].
COPD is a progressive, life-threatening, chronic lung
disorder, that is characterized by airﬂow limitation that is
poorly reversible, airway and systemic inﬂammation, struc-
tural changes (airway remodeling, emphysema), and muco-
ciliary dysfunction [10]. The World Health Organization
(WHO) has estimated that about 210 million people have
COPD and predicts that COPD will become the third leading
cause of death by 2030 [11].
The therapeutic goals for patients with COPD include relief
of symptoms, improving health status, preventing and
treating exacerbations, slowing the progression of disease
and reducing mortality [12,13]. Viewed from the patient's
perspective, symptoms affecting health status, activities of
daily living, survival, and exacerbations are relevant out-
comes [14–16]. Measurement of pulmonary function alone
may not adequately reﬂect the burden of COPD on patients
and the effectiveness of therapeutic interventions [17]. Self-
report of symptoms and health status, therefore, is essential
for evaluating treatment outcome [18–22].
Current guidelines for the management of COPD recom-
mend the use of long-acting inhaled bronchodilators for
patients with symptomatic moderate and severe disease with
the addition of inhaled corticosteroids (ICS) for patients who
experience repeated exacerbations [4]. Indacaterol is a novel,
once-daily inhaled long-acting β2-agonist (LABA) for the
treatment of COPD and studies [23–28] have reported that it
increases lung function alongside improving patient-reported
symptoms and health status. The clinical trials in the
development program for indacaterol provided data that
allowed an opportunity to carry out an exploratory analysis to
ascertain if new techniques could be applied to identify
unobserved subgroups of patients exhibiting differential
response to outcomesdrawndirectly frompatient experience—
self-reported symptoms. The randomized controlled studies
included twice-daily LABAs (salmeterol and formoterol), and
the once-daily anticholinergic tiotropium, which were evalu-
ated using a range of lung-function and clinical outcome
endpoints including patient-reported COPD symptoms [29–
31].
The present analysis applied LGM and GMMmethodology
to examine variability in symptom response data reported by
patients with COPD to identify subgroups of patients whose
self-reported symptoms exhibited greater or lesser change.
Patients showing different symptom responses were charac-
terized into different responder subgroups to understand
better how they differed on baseline characteristics.2. Methods
2.1. Datasets analyzed
Two 6-month trials and one 12-month trial were used for
the present analyses. All trials were multi-national, multi-
center, double blind, double dummy, placebo-controlled
trials with an active comparator. The INHANCE study
compared indacaterol 150 μg and 300 μg with placebo and
open-label tiotropium 18 μg for six months, randomizing
patients at 1:1:1:1 [31]. The INLIGHT-2 study compared
indacaterol 150 μg with placebo and blinded salmeterol 50 μg
for six months, randomizing patients at 1:1:1 [29]. The third
study, INVOLVE, was a 12-month trial that compared
indacaterol 300 μg and 600 μg with placebo and blinded
formoterol 12 μg, randomizing patients at 1:1:1:1 [30]. Only
data from the ﬁrst six months of INVOLVE were used to keep
the analyses comparable across the three trials.
Since the objective of this study was the application of
novel analytic methods, all treatment arms (including
placebo and the unlicensed 600 μg dose of indacaterol)
were included. Details of the trials are reported in the
publications referenced above but brieﬂy all trials had the
following inclusion criteria: male and female patients aged
≥40 years; diagnosis of moderate-to-severe COPD as classi-
ﬁed by GOLD guidelines (2005); smoking history of at least 20
pack-years; post-bronchodilator forced expiratory volume in
1 s (FEV1) b80% and≥30% of the predicted normal value; and
post-bronchodilator FEV1/FVC (forced vital capacity) b70%.
All patients were supplied with the short-acting β2-agonist
salbutamol/albuterol for use as rescue medication.
2.2. Assessments
Measurement of lung function (FEV1) was the primary
endpoint in the trials but symptoms based measures were
also included: The St George's Respiratory Questionnaire
(SGRQ) was used to measure COPD health status. In addition,
breathlessness was captured with the modiﬁed Medical
Research Council dyspnea scale (mMRC) and the Baseline
and Transition Dyspnea Indices (BDI/TDI). In the present
analyses only data from the SGRQ and mMRC were used for
all trials, from baseline, week 12 and six months. These
measures are described below.
2.2.1. Modiﬁed Medical Research Council dyspnea scale
(mMRC)
The clinician rated the degree of the participant's dyspnea
on the mMRC dyspnea scale [32]. The mMRC is a ﬁve point
scale based on degrees of physical activities that may lead to
dyspnea, ranging from 0 (“no breathlessness except with
strenuous exercise”) to 4 (“too breathless to leave the house
or breathless when dressing or undressing”).
2.2.2. St George's Respiratory Questionnaire (SGRQ)
The SGRQ is a validated patient-reported outcome (PRO)
measure of health status in diseases of chronic airﬂow
limitation and has been widely used in clinical trials in
COPD [33,34]. It contains 50 items divided into three
subscales: “Symptoms”, “Activity”, and “Impacts”. A score
for each subscale was calculated, alongside “Total” score. In
820 D.E. Stull et al. / Contemporary Clinical Trials 32 (2011) 818–828each case the lowest possible value was zero and the highest
100. Higher values correspond to greater impairment in
health status. The Symptoms domain was selected for this
exploratory analysis given the importance of symptoms to
patients, and because active treatments tend to show the
greatest level of improvement in this domain [28,35,36].
3. Statistical analysis
Overview: Descriptive statistics are presented for the
INHANCE, INLIGHT-2 and INVOLVE studies separately. The
effect of treatment over time and effect sizes with regards to
the clinical assessments and patient-reported symptoms
using the SGRQ Symptoms domain scores are presented
separately for each study. In addition, two types of longitu-
dinal analyses were conducted based on the data at baseline,
week 12, and six months for each study: latent growth
modeling and growth mixture modeling. In both sets of
analyses, the models included the following covariates to be
as similar as possible to the original clinical trial analyses:
COPD severity, smoking status, baseline FEV1, age, and
gender.
Latent growth models (LGM) were used to explore the
response of the SGRQ Symptom domain score from baseline
to six months across the three assessment points (baseline,
12 weeks, and six months) controlling for key covariates.
Latent growth models use structural equation modeling
techniques to model trajectories of change, assess effects of
treatment, and consider the relationships among multiple
outcome variables and multiple time points simultaneously.
In LGM analysis, changes in scores are analyzed at the
individual level, by generating an intercept and slope of
change for each individual, thus modeling individual vari-
ability in treatment response. Intra- and inter-individual
changes are assessed using all available data points and
modeling measurement error, which is especially important
in analysis of patient-reported outcomes data. The conse-
quence is more precise parameter estimates while using data
from all available time points [5]. More detailed descriptions
of these models are presented elsewhere [5], but a brief
description is provided here.
An intercept and slope of change in the SGRQ Symptom
score is based on the manifest composite score for this
domain at each assessment point. Thus, each growth curve is
characterized by two latent variables: a variable for the ﬁrst
time point of the curve, labeled as “intercept”, and a variable
for changes in the scores over time, labeled “slope”. Note that
the intercept variable is not equivalent to the value of the
initial observation for a patient (i.e., baseline score), but
rather the value of the growth curve at the start of the trial for
each patient, adjusted for covariates. Thus, the intercept and
slope variables havemeans and variances reﬂecting the mean
intercepts and mean slopes of change and the variability in
individual intercepts and slopes [5].
Typically in an LGM, each intercept variable is allowed to
be correlated with the corresponding latent slope variable.
That is, an underlying hypothesis that is tested is that a
change in the slope variable is related to the value of the
baseline variable. Thus, this parameter is estimated to see if
those who start with a higher (worse) SGRQ Symptom score
show greater improvements. Dyspnea, as measured by themMRC, was modeled as a time-varying covariate to contribute
to controlling the analysis for the level of breathlessness at
each assessment, which could in turn inﬂuence SGRQ
Symptom score. For each treatment group, a mean intercept
and slope is calculated (along with a variance around that
mean) which allows the analyst to compare intercepts but,
more importantly, to compare differences in slope of change in
the SGRQ Symptom scores by treatment groups over the trial.
Growth mixture models (GMM) analyses (longitudinal
factor mixture models) were used to see if latent classes
(unknown subgroups) existed in the trial data, allowing
identiﬁcation of differential responders in the studies [6].
Mixture modeling refers to modeling with categorical latent
variables that represent subpopulations where class mem-
bership is not known but is inferred from the data [6,37,38].
Mixture models are designed for data from heterogeneous
samples likely to consist of multiple latent classes, each of
which is relatively homogeneous.
Mixture modeling was used to assign subjects to their
most likely class and to obtain estimates of the model
parameters for each class. Growth mixture models were
conducted using Mplus version 6.0. In a preliminary run, the
software determined a number of latent classes (k) within
each treatment arm. A second run was performed with
different start values to reduce the chance of local maxima
and to determine whether the same number of classes would
be extracted, and if the class assignment was consistent.
Following this, analyses were performed with k−1 and/or
k+1 classes to evaluate which number of classes extracted
yielded the best model ﬁt. The Bayesian Information Criteria
(BIC) and Sample-size Adjusted BIC (SABIC) were the
primary ﬁt statistics used to determine the number of
classes that best ﬁt the data, along with entropy, which
gives an indication of the accuracy of latent class assign-
ment for each respondent [39,40], and the size of the
smallest latent class that was extracted. Very small classes
may represent chance ﬁndings and thus give a false
indication of the number of latent classes within the
heterogeneous data. In case a model did not converge (i.e.
the model was not able to run) for a speciﬁed number of
latent classes, the remaining models were compared and
the one with the best combination of BIC, SABIC and entropy
value was chosen. Smaller values of BIC and SABIC are
preferred when choosing the number of latent classes [40].
Although there is no conventional level for the threshold
value for entropy, values closer to 1 indicate greater
accuracy of latent class assignment. Multiple random starts
were used to avoid solutions based on local maxima, which
would give a false sense of the number of latent classes in
the data. In addition, visual inspection of the latent class
trajectories provided insight into the reasonableness of the
numbers of latent classes to be considered. Once classes
were extracted, class ordering and separationwere explored as
a ﬁnal check on the appropriateness of the number of latent
classes extracted. Review of the information from ﬁt statistics,
smallest class size, and visual inspection of the slope
trajectories by latent class was used to make ﬁnal decisions
about the numbers of latent classes to be extracted. The latent
class assignment for each patient was then merged with the
original trial data to explore baseline characteristics of each
class in post hoc analyses.
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Results for all three trials are presented in detail in this
section.
4.1. Sample description
The patients' characteristics at baseline are shown in
Table 1 and indicate that the patient populations in the three
studies were similar, although a slightly higher proportion of
patients in INVOLVE were male and were using ICS at baseline.
None of the variables used in these analyses had distributions
that were non-normal (statistics not shown). For example,
skewness ranged from−0.35 to 0.92; kurtosis ranged from 1.1
to 3.8.
4.2. Latent growth models
Figs. 1, 2, and 3 show the slopes for the growth curve
models for INHANCE, INLIGHT-2, and INVOLVE for the SGRQ
Symptom domain scores, with the mMRC dyspnea as a time-
varying covariate, controlling for gender, age, baseline COPD
severity and FEV1, and smoking status. The growth curves for
SGRQ Symptom domain scores were linear for each trial,
showing a decrease (improvement) for all groups over the
course of INHANCE and for each active treatment group in
INLIGHT-2 and INVOLVE (Figs. 1, 2, and 3, respectively). We
assessed quadratic curves, but either the models did not
converge or there was no improvement in ﬁt, thus indicating
that a straight linear slope adequately ﬁt the data.
The results showed a greater overall improvement at six
months for both doses of indacaterol over placebo in INHANCE,
with a signiﬁcant advantage at the end of the study for
indacaterol 300 μg over tiotropium (pb0.01; Fig. 1). The slopes
of change (i.e. trajectory from baseline to end of study) for both
indacaterol 150 μg and 300 μgwere signiﬁcantly different from
that of tiotropium (t=−3.73, pb0.001 and t=−5.23,
pb0.001, respectively), indicating a greater overall rate of
improvement with indacaterol than tiotropium.
There was a signiﬁcant overall advantage of indacaterol
150 μg over placebo at weeks 12 and six months in INLIGHT-2
(t=−3.84, pb0.001; t=−3.46; pb0.001, respectively;
Fig. 2). Salmeterol also showed a signiﬁcant advantage over
placebo at weeks 12 and six months (t=−3.03, pb0.01; t=
−2.73, pb0.01, respectively). There was no signiﬁcant
difference in slopes of change between indacaterol 150 μg
and salmeterol, though both were signiﬁcantly different from
placebo (t=−7.98, pb0.001 and t=−7.95, pb0.001, respec-
tively; Fig. 2).
There were no signiﬁcant differences in SGRQ Symptom
scores between either dose of indacaterol (300 μg or 600 μg)
or formoterol relative to placebo at six months in INVOLVE.
This appears to have been a function of the amount of
variability in each slope. Likewise, there were no signiﬁcant
differences between either dose of indacaterol and formo-
terol. However, signiﬁcant advantages of indacaterol 300 μg,
600 μg and formoterol were found relative to placebo in the
slopes of change (i.e., improvement over six months: ind
300 μg vs. placebo t=−4.95; ind 600 μg vs. placebo t=
−7.03; formoterol vs. placebo t=−5.35; pb0.001 for all
comparisons; see Fig. 3). That is, the slopes of change for the
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Fig. 1. Growth curves of SGRQ symptoms with mMRC dyspnea as a time-
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Fig. 3. Growth curves of SGRQ symptoms with mMRC dyspnea as a time-
varying covariate — INVOLVE.
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placebo.
4.3. Growth mixture models
There was substantial variability around SGRQ scores
(intercepts and slopes) in all trials (see Table 2), as indicated
by standard deviations for the intercepts that were in excess
of 30% of the magnitude of the mean scores, and with
standard deviations that were often similar in magnitude of
the means of the slopes. Although no convention appears to
exist about how much variability should exist to recommend
conducting mixture models, the high level of variability
around the mean intercepts and growth trajectories within
the present data may indicate subsets of patients who
respond differently to treatment, but are masked when
analyzing group means as a whole. Thus, it was deemed
appropriate to apply GMM analysis to see if it would identify
subgroups of differential responders hidden in this variability
in SGRQ Symptom scores.
Table 3 presents the ﬁt information used to make
decisions about the acceptable number of latent classes
extracted. For INHANCE and INLIGHT-2, the BIC and SABIC
were marginally smaller for the 3-class solution, however,
entropy was larger for the 2-class solution, especially for0 
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Fig. 2. Growth curves of SGRQ symptoms with mMRC dyspnea as a time-
varying covariate — INLIGHT-2.INLIGHT-2. The smallest class size was slightly better for the
2-class solution for INHANCE. However, visual inspection of
the growth trajectories of the 2- and 3-class solutions
suggested clearer class distinctions and greater class separa-
tion (i.e., clearer differences in baseline scores and slopes) for
the 2-class solutions. Thus, 2-class solutions were selected for
these two trials. In contrast, for INVOLVE the results were
somewhat mixed. The BIC and SABIC were clearly better for
the 3-class solution, but entropy and smallest class size was
better for the 2-class solution. However, visual inspection of
the intercepts and slopes for the 2- versus 3-class solutions
clearly favored to 3-class solution. There was much clearer
separation of classes in terms of intercepts and slopes for the
3-class solution, whereas the 2-class solution resulted in
intercepts and slopes that were not easily interpretable.
For INHANCE and INLIGHT-2, there were two distinct
subsets of patients, based on response to the SGRQ Symptoms
domain: one smaller subset of patients had high (poor) SGRQ
Symptoms scores at baseline and these changed little, or in
some instances deteriorated (Figs. 4 and 5; also see Table 4 for
mean SGRQ Symptom scores by latent class). This subgroup is
referred to as ‘non-responders’ due to the lack of improve-
ment (i.e., decrease) in SGRQ Symptom scores. These non-
responders – one slope per treatment arm – accounted for
21.5% of the entire trial sample in INHANCE and 18.2% in
INLIGHT-2.
In INHANCE the subset of non-responders had substan-
tially higher baseline SGRQ symptom scores than responders
and changed very little over the six months (Fig. 4). Non-
responders showed a slight decrease (improvement) in mean
SGRQ symptom scores at six months (ranging from−1 to−4
[indicating improvement] for treatment and +1 [indicating
deterioration] for placebo — see Table 4), while SGRQ symp-
tom scores for responders were substantially lower (better)
when non-responders were modeled separately (ranging
from −8 to −12 for treatment and −8 for placebo —
see Table 4). With non-responders modeled separately,
tiotropium and placebo showed similar overall slopes of
change in SGRQ Symptom scores and both showed less
overall improvement in SGRQ Symptom scores than either
indacaterol dose (see Table 4).
Table 2
LGM mean intercept and change, by treatment group: SGRQ symptom domain.
INHANCE INLIGHT-2 INVOLVE
Intercept
(SD)
Slope: baseline–six months
(SD)
Intercept
(SD)
Slope: baseline–six months
(SD)
Intercept
(SD)
Slope: baseline–six months
(SD)
IND150 (N=416) 54.1 (19.5) −13.5 (5.6)
IND300 (N=416) 52.0 (18.9) −11.7 (6.0)
PLAC (N=418) 51.1 (18.5) −5.1 (4.8)
TIOT (N=415) 52.3 (20.6) −6.8 (5.2)
IND150 (N=330) 45.7 (18.4) −6.1 (8.1)
PLAC (N=335) 48.0 (19.3) −3.1 (6.1)
SALM50 (N=333) 47.6 (19.1) −8.0 (5.5)
IND300 (N=437) 48.0 (17.5) −7.6 (2.1)
IND600 (N=425) 49.1 (17.8) −9.9 (2.6)
FORM (N=434) 52.7 (18.4) −10.9 (3.0)
PLAC (N=432) 52.9 (19.9) −2.6 (2.4)
Note: IND = indacaterol; TIOT = tiotropium; SALM = salmeterol; PLAC = placebo.
823D.E. Stull et al. / Contemporary Clinical Trials 32 (2011) 818–828As with INHANCE, the subset of non-responders in
INLIGHT-2 emerging from the GMMs (the three slopes near
the top of Fig. 5, one slope per treatment arm) showed a slight
worsening in their scores fromweek 12 to month six and had
SGRQ Symptom scores at baseline and across the trial that
were substantially higher (poorer) than did the main
treatment group from which they emerged (difference from
baseline to six months ranged from −1 to +4 for treatment
and +3 for placebo — see Table 4). Mean SGRQ Symptom
scores for indacaterol 150 μg and salmeterol were substan-
tially lower (better) when responders were modeled sepa-
rately to non-responders (ranging from −11 to −13 for
treatment and −3 for placebo — see Table 4).
GMM results for the INVOLVE study were, in some
respects, different from those of INHANCE and INLIGHT-2.
In particular, the GMMs for INVOLVE were the only analyses
in which three sets of latent classes emerged (see Fig. 6). The
three classes identiﬁed by the GMM analyses exhibited three
different patterns of trajectories and were labeled ‘re-
sponders’, ‘partial-responders’ or ‘non-responders’.
As shown in Fig. 6, non-responders had slightly higher
SGRQ symptom scores at baseline compared to responders
and showed a slight worsening in their scores from week 12
to month six. The difference from baseline to six months
for non-responders ranged from+1 to +3 for treatment and
was −2 for placebo. When non-responders and partial-
responders were modeled separately, symptom scores wereTable 3
Model ﬁt information for the number of latent classes extracted.
INHANCE INLIGHT-2 INVOLVE
2-Class solution
BIC 36404.9 23646.3 41224.8
SABIC 36284.2 23544.6 41078.6
Smallest class size 4.8% 5.3% 5.0%
Entropy 0.9 0.9 0.9
3-Class solution
BIC 36449.1 23669.0 38447.5
SABIC 36283.9 23532.4 38285.5
Smallest class size 4.1% 6.5% 3.9%
Entropy 0.8 0.8 0.8substantially greater for the indacaterol and formoterol
responder groups — improvement from baseline to six
months ranged from −14 to −17 for treatment and was
−5 for placebo (see Table 4). Partial-responders had
substantially lower baseline scores than responders or non-
responders and exhibited less overall change in SGRQ
Symptom scores compared with the overall treatment groups
seen in the LGMs (ranging from−7 to−8 for treatment and
−7 for placebo; see Figs. 3 and 6 and Table 4).
4.4. Characterizing the latent classes
Once the latent classes of differential responders were
identiﬁed, the next step involved describing their baseline
characteristics to see if and how the classes differed.
Responders and non-responders (and partial-responders in
INVOLVE) were then examined to identify if there were
characteristics of each that were unique (see Table 5).
Comparisons were made between responder groups on
baseline respiratory characteristics and patient age. All
comparisons used p≤0.05. Patient race was examined, but
no tests of differences were calculated. Note that although
multiple comparisonsweremade, no adjustments weremade
for multiplicity as these post hoc analyses were largely
exploratory. It should be noted that half of the comparisons
were statistically signiﬁcant at or below 0.05.
Responders compared to non-responders had a lower (i.e.,
better) score on the SGRQ Symptom domain at baseline,
lower (better) mMRC dyspnea score, were less likely to be a
current smoker, and were older than the non-responders. For
INVOLVE, compared with partial-responders, responders had
a higher mean baseline SGRQ Symptom score, were signiﬁ-
cantly more likely to be current smokers, were signiﬁcantly
younger and had signiﬁcantly worse baseline dyspnea.
5. Discussion
In this exploratory analysis, analytic methods were used
to identify unobserved subgroups of patients with differential
growth trajectories to those of other subgroups. This
approach has the potential to increase understanding of
treatment effects and identify patients more or less likely to
0 
38 
42 
46 
50 
54 
58 
62 
66 
70 
74 
78 
82 
Non-responder IND150, 4.8%
Responder IND150, 20.4%
Non-responder IND300, 6.6%
Responder IND300, 20.0%
Non-responder PLAC, 4.9%
Responder PLAC, 17.6%
Non-responder TIOT, 5.2%
Responder TIOT, 20.6%
12 Weeks 6 Months
Treatment Time Point 
SG
RQ
 S
ym
pt
om
 S
co
re
NOTE: Patient  age, sex, GOLD stage of COPD severity, smoking status,
 and baseline FEV1
 
are covariates 
Fig. 4. Growth mixture models of SGRQ symptoms with mMRC dyspnea as a
time-varying covariate — INHANCE.
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potentially inform the development of future trials and
increase treatment effectiveness by tailoring programs for
relevant populations. Therefore, we evaluated the utility of
GMMs in identifying unobserved subgroups by analyzing
SGRQ Symptom scores over the course of three COPD trials.
Once identiﬁed, these subsets of patients were examined to
yield a clearer picture of those patients who are most likely to
show a positive response to treatment.
The use of GMM is a relatively recent analytic tool for
examining heterogeneity in responses in clinical trial data,
particularly when examining patterns of change. The LGM
technique in the present evaluation resulted in linear growth
curves for two 6-month trials and the ﬁrst six months of a 12-
month trial. These results indicated a decrease (improve-
ment) in SGRQ Symptom scores for all active treatment
groups.
The GMM analyses examined the variability in responses
to the SGRQ Symptoms domain and identiﬁed two distinct
subsets of patients in both 6-month trials that exhibited
differential treatment response. While the proportion of non-
responders within each trial was not exceptionally large, each
subgroup was large enough and their SGRQ Symptoms scores
different enough from that of the responders to have a
noticeable effect on the slopes of change, when combined0 
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Fig. 5. Growth mixture models of SGRQ symptoms with mMRC dyspnea as a
time-varying covariate — INLIGHT-2.with their respective main treatment groups. The subsets of
non-responder patients had high (poor) SGRQ Symptoms
scores at baseline. Over the 6-month study period of
INHANCE and INLIGHT-2, these scores showed little change
and pulled the mean scores of the main treatment groups
toward a higher (worse) value. Consequently, this subset
negatively affected the overall group scores. That is, in the
LGMs there was less apparent, overall improvement in the
mean SGRQ Symptom scores and slopes of change in the
treatment groups when non-responders were not identiﬁed
separately, but were part of their respective, original
treatment arms. Modeling the non-responders separately
resulted in a greater apparent treatment effect on self-
reported symptoms for all active treatments in both trials,
and a differentiation for indacaterol against placebo in both 6-
month studies and the comparator in INHANCE.
The 6-month analysis of the INVOLVE trial showed that a
subset of non-responders also emerged. Unlike the other two
studies, in INVOLVE three latent classes emerged: non-
responders, responders, and partial-responders (patients
who showed some treatment response but not as great as
those in the responder class). Although scores for responders
were consistently between those of the other two classes in
INVOLVE, they were almost identical to those of the re-
sponders in INHANCE and INLIGHT-2; the non-responder
scores were also consistent between the three studies. The
partial-responders began the trial with quite low SGRQ
Symptom scores and dropped, on average, about 6–8 points,
compared with 14–21 points for the responders. They were
also the class with the best overall baseline characteristics,
but were signiﬁcantly older. So, for the patients in INVOLVE it
appears that those in better health and with better baseline
SGRQ Symptom scores are less likely to show the dramatic
improvement seen in responders.
A key treatment goal in COPD is symptomatic improve-
ment and accordingly the present post hoc evaluation
analyzed the Symptom domain of the SGRQ as a way of
more closely assessing the symptomatic effects of COPD
treatment. In the absence of pre-deﬁned responders/non-
responders (as in the case with the SGRQ Symptoms domain)
GMMs can identify such subgroups efﬁciently and post hoc
comparisons can help in understanding the differences
between subgroups.
The analyses included several rigorous decision points
about the signiﬁcance of the latent subgroups and the
credibility of the number and constitution of the subgroups.
It is clear in the present analyses that the combined use of
empirical and qualitative (i.e., visual) results aids in decisions
on the optimal number of latent classes to extract. Once the
latent class solution was selected for each trial, the sizes and
the consistency of sizes of the latent subclasses, and similarity
of the baseline scores and slopes of change within each of
trials added conﬁdence that the solutions selected were the
most likely. Even in INVOLVE, the non-responders and
responders were very much like those in the other two trials.
So it appears that common processes and experiences are
working in all three trials, but something unique – the partial-
responders – occurred in the INVOLVE trial.
The GMM analyses used in the present study demonstrate
that the use of this relatively recent analytic approach to
examining change and variability in responses can aid in
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825D.E. Stull et al. / Contemporary Clinical Trials 32 (2011) 818–828detecting subgroups exhibiting differential change efﬁciently
with statistical tests that can increase conﬁdence in the
results. The GMM analyses made it possible to determine
whether certain subgroups were more or less responsive to
treatment, helping to explain the overall variability in
treatment response.
Predictably, a post hoc analysis of this type has limitations.
First, there were no pre-deﬁned subgroups of patients, or pre-
determined analyses. It may be argued that this type of
subgroup analysis is exploratory and represents a starting
point for subsequent conﬁrmatory analyses or clinical trials.
That is, the results of analyses of only one study would only
constitute exploratory ﬁndings until conﬁrmed with analyses
of an additional study. However, the opportunity to replicate
the analyses in this study in similar trials, and the consistency
of many of the results, increased our conﬁdence in the results.
Second, notwithstanding the similarities in design of the two
6-month clinical trials, the treatment options were not identical
necessitating the analysesof each study individually thus limiting
the numbers of patients in each non-responder subgroup.
Finally, the SGRQ Symptom scale is not validated as a
standalone subscale; only the SGRQ Total score is. Nonethe-
less, it focuses more closely on the symptom experience of
patients with COPD and showed differences in change
between active treatment groups and placebo, giving us
greater opportunity to detect patient sub-groups.
Randomized control trials are designed to ensure that
each treatment arm has a similar amount of heterogeneity
due to patient randomization. This does not preclude
consideration of signiﬁcance tests on baseline characteristics
[41]. However, in the absence of baseline differences,
heterogeneity in treatment response can still exist and may
result from inﬂuences outside the design of the trial,
including differences in genetic makeup of patients. This
heterogeneity in treatment response is often reﬂected in large
variations around group means. Examining heterogeneity in
treatment response can yield new insights into treatment
efﬁcacy [42]. The present analyses showed that when
subgroups of non-responders are identiﬁed and modeled
clearly, there are subsets of patients with COPD that exhibit
an even more pronounced symptom relief from treatment
than was apparent with a focus on the main trial treatment
groups. This was evident from the progressive improvement
in SGRQ Symptoms during the 6-month study periods. The
characteristics of these subgroups produce insights into
differences between responders and non-responders, and
from a clinical practice perspective, could provide useful
information regarding identiﬁcation of patients likely to
beneﬁt the most from the treatment.
GMMs provide a way to analyze responses at an individual
level and thus investigate whether there are subsets of
differential responders that are masked when whole group
means are analyzed. If included early in a clinical trial
program, the results can provide insights into subgroups
most/least likely to respond to treatment. This information
could inform the design of later trials thereby reducing
heterogeneity and providing a more accurate assessment of
treatment efﬁcacy. However, the extent to which subgroups
of differential responders can be adequately characterized
depends largely on the extent of data collected as part of the
study. Pharmaceutical companies intending to apply this
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Fig. 6. Growth mixture models of SGRQ symptoms with mMRC dyspnea as a
time-varying covariate — INVOLVE.
826 D.E. Stull et al. / Contemporary Clinical Trials 32 (2011) 818–828methodology in their trials should anticipate factors that
result in heterogeneity of response and design studies to
collect data that could be used in post hoc analyses to
characterize the subgroups of differential responders. This
could reduce the chances of ﬁnding subgroups who are more
responsive to treatment but who cannot be clearly deﬁned on
observed characteristics.
6. Conclusion
Patients with COPD represent a heterogeneous population
in terms of their reporting of symptoms and response to
treatment. The GMM analyses provided greater insight intoTable 5
Baseline differences between responders and non-responders: based on latent clas
Variable INHANCE INLIGHT-2
Non-responders Responders Non-respon
(n=252) (n=729) (n=158)
SGRQ symptoms domain: mean 73.7 50.5⁎⁎⁎ 79.3
Smoking history (% smoker) 60% 40%⁎⁎⁎ 70%
Baseline FEV1 1.3 1.3 1.3
COPD severity (GOLD) n (%)a
At risk 0 (0%) 1 (0.1%) 0 (0%)
Mild 13 (5.2%) 26 (3.6%) 0 (0%)
Moderate 130 (51.6%) 424 (58.2%) 76 (48.1%)
Severe 109 (43.3%) 277 (38.0%) 82 (51.9%)
Very severe 0 (0%) 1 (0.1%) 0 (0%)
Patient age 61.8 64.0⁎⁎⁎ 61.8
MMRC baseline dyspneaa 1.9 1.6⁎⁎⁎ 1.7
Reversibility (SABA)b 1.5 1.5 1.4
Reversibility (anti-cholinergic)c 1.6 1.5 1.5
Race
White 231 (95.6) 581 (84.9) 151 (95.6)
Black 10 (4.0) 14 (2.1) –
Asian 9 (3.6) 80 (11.7) –
Other 2 (0.8) 9 (1.3) 7 (4.4)
a 1 = not troubled by breathlessness except in strenuous exercise, 5 = too brea
b = demonstrated increase in FEV1 compared to the pre-bronchodilator value, w
c = demonstrated increase in FEV1 compared to the pre-bronchodilator value, 1
d = difference (pb0.05) between non-responders and partial-responders.
e = difference (pb0.05) between non-responders and responders.
f = difference (pb0.05) between partial-responders and responders.
⁎ pb0.05.
⁎⁎ pb0.01.
⁎⁎⁎ pb0.001.treatment response than was evident with the LGMs. We
found that the GMMmethods are able to identify sub-groups
of responders and non-responders to the SGRQ symptoms
component score and that when the responders are analyzed
separately from the non-responders there are increased
treatment effects and, in some cases, increased differences
between treatments. Application of this novel methodology
could be of value in examining other endpoints in COPD and
other disease areas. Future work could involve studying the
accuracy of classifying patients to their respective responder
groups based on the baseline predictor variables.
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ders Responders Non-responders Partial-responders Responders
(n=671) (n=300) (n=284) (n=797)
48.3⁎⁎⁎ 73.3 24.6d 60.4e, f
40%⁎⁎⁎ 50% 30%d 40%f
1.3 1.3 1.4d 1.3f
3 (0.5%) 10 (3.3%) 2 (0.7%) 12 (1.5%)
18 (2.7%) 3 (1.0%) 7 (2.5%) 13 (1.6%)
377 (56.2%) 146 (48.7%) 172 (60.6%) 420 (52.7%)
272 (40.5%) 136 (45.3%) 100 (35.2%) 342 (42.9%)
1 (0.2%) 5 (1.7%) 3 (1.1%) 10 (1.3%)
63.7⁎ 62.5 65.2d 63.6f
1.5⁎ 1.9 1.4d 1.6e, f
1.5 1.5 1.6d 1.5
1.5 1.5 1.6d 1.5f
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126 (18.8) 6 (2.0) 2 (0.7) 16 (2.0)
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thless to leave house, or breathless when dressing or undressing.
ithin 30 min after inhalation of 4×100 μg puffs of salbutamol/albuterol.
h after inhalation of 2×21 μg ipratropium bromide.
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